GAMA
BOLD

Graticule Asia Macro Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

Graticule Asia Macro Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-35,059
Closed -$1.35M – 164
2019
Q1 		$1.37M Buy
+35,059
New +$1.01M 0.1% 93

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Graticule Asia Macro Advisors's BOLD Position: Q2 2019 in Review

Graticule Asia Macro Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q2 2019, closing a stake of 35,059 shares — an estimated $1.35M sold.

Graticule Asia Macro Advisors first reported a position in BOLD in Q1 2019 and held it in 1 quarter. The position peaked at $1.37M in Q1 2019. 147 funds tracked by Wall St. Rank hold BOLD as of Q2 2019.

  • Graticule Asia Macro Advisors reported no remaining Audentes Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 35,059 Audentes Therapeutics, Inc shares in Q2 2019, an estimated $1.35M.
  • Graticule Asia Macro Advisors first reported a position in Audentes Therapeutics, Inc in Q1 2019 and held it in 1 quarter.
  • Graticule Asia Macro Advisors's Audentes Therapeutics, Inc position peaked at $1.37M in Q1 2019.
  • 147 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2019.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.